ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
7.44
+0.35 (4.94%)
After Hours: 7.44 0.00 (0.00%)
Apr 26, 7:35PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.00 - 7.50
52 week 4.45 - 8.72
Open 7.11
Vol / Avg. 1.48M/1.34M
Mkt cap 1.02B
P/E     -
Div/yield     -
EPS -1.32
Shares 132.38M
Beta 1.55
Inst. own 46%
Jun 5, 2017
ZIOPHARM Oncology, Inc. - Special Call - 2:15PM EDT - Add to calendar
May 8, 2017
Q1 2017 ZIOPHARM Oncology Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 1, 2017
Q1 2017 ZIOPHARM Oncology Inc Earnings Call - 4:30PM EDT - Add to calendar
Feb 16, 2017
Q4 2016 ZIOPHARM Oncology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -702.82% -2409.23%
Operating margin -695.74% -2409.37%
EBITD margin - -2405.14%
Return on average assets -40.29% -127.12%
Return on average equity - -3423.41%
Employees 36 -
CDP Score - -

Address

One First Avenue Parris Building 34 Navy Yard Plaza
BOSTON, MA 02129
United States - Map
+1-646-2140700 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Officers and directors

Laurence James Neil Cooper M.D., Ph.D. Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Kevin G. Lafond CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 58
Bio & Compensation  - Reuters
Caesar J. Belbel Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
Age: 55
Bio & Compensation  - Reuters
Murray Brennan Non-Executive Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 62
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 76
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 75
Bio & Compensation  - Reuters
Timothy McInerney Independent Director
Age: 54
Bio & Compensation  - Reuters